| In millions, except per share items | Dec-31-09 | Dec-31-08 | Dec-31-07 | Dec-31-06 | Dec-31-05 | Dec-31-04 | Dec-31-03 | Dec-31-02 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | S-1/A |
| Revenues: |
| Manufactured Products | 16.7 | 11.9 | | | | | | |
| Licensed Products | 0.8 | 49.1 | 30.9 | | | | | |
| Pharmaceutical Distribution | | | | 24.2 | 4.0 | | | |
| Other | 129.4 | 53.9 | 0.1 | 0.1 | 0.2 | | | |
| Total revenues | 146.9 | 114.9 | 31.0 | 24.3 | 4.2 | 0.2 | 0.9 | 1.0 |
| Revenue growth [+] | 27.9% | 270.5% | 27.8% | 480.5% | 1896.7% | -77.6% | -7.5% | 1.6% |
| Manufactured Products | 39.9% | | | | | | | |
| Licensed Products | -98.5% | 58.9% | | | | | | |
| Pharmaceutical Distribution | | | | 505.1% | | | | |
| Cost of goods sold | 72.9 | 57.6 | 26.7 | 22.3 | 5.0 | 0.3 | 0.7 | 0.8 |
| Gross profit | 74.0 | 57.3 | 4.3 | 1.9 | -0.8 | -0.1 | 0.3 | 0.2 |
| Gross margin | 50.4% | 49.9% | 13.8% | 8.0% | -19.2% | -51.8% | 28.7% | 20.8% |
| Selling, general and administrative [+] | 65.6 | 53.6 | 15.2 | 8.5 | 4.8 | 2.3 | 0.3 | 0.3 |
| Sales and marketing | 47.8 | 39.7 | 4.4 | 2.7 | 0.4 | 0.1 | 0.0 | 0.1 |
| General and administrative | 17.8 | 13.9 | 10.8 | 5.8 | 4.4 | 2.2 | 0.2 | 0.3 |
| Other operating expenses | | | | | | | 0.0 | 0.1 |
| EBITDA [+] | 10.8 | 5.6 | -10.8 | -6.0 | -5.5 | -2.4 | 0.0 | 0.0 |
| EBITDA growth | 93.7% | -151.9% | 80.3% | 8.7% | 132.0% | -22698.4% | -79.0% | -233.0% |
| EBITDA margin | 7.4% | 4.9% | -34.7% | -24.6% | -131.3% | -1130.2% | 1.1% | 4.9% |
| Depreciation | 2.4 | 1.8 | 0.1 | 0.3 | 0.1 | 0.0 | 0.0 | 0.2 |
| EBITA | 8.4 | 3.7 | -10.9 | -6.3 | -5.6 | -2.4 | 0.0 | -0.2 |
| EBITA margin | 5.7% | 3.3% | -35.1% | -26.0% | -133.3% | -1133.7% | 0.9% | -16.8% |
| Amortization of intangibles | | | | 0.3 | 0.0 | | | |
| EBIT [+] | 8.4 | 3.7 | -10.9 | -6.6 | -5.6 | -2.4 | 0.0 | -0.2 |
| EBIT growth | 123.9% | -134.5% | 65.5% | 17.0% | 136.6% | -29760.2% | -104.7% | 353.4% |
| EBIT margin | 5.7% | 3.3% | -35.1% | -27.1% | -134.3% | -1133.7% | 0.9% | -16.8% |
| Non-recurring items [+] | | | | 0.4 | | | | |
| Loss (gain) on sale of assets | | | | 0.4 | | | | |
| Interest expense, net [+] | 4.2 | 6.2 | 0.4 | -0.1 | 0.0 | -0.1 | 0.0 | 0.0 |
| Interest expense | 4.4 | 6.3 | 1.0 | 0.1 | 0.2 | 0.0 | 0.0 | 0.0 |
| Interest income | 0.2 | 0.1 | 0.6 | 0.2 | 0.2 | 0.1 | | |
| Other income (expense), net [+] | -3.8 | -0.2 | -0.3 | 0.0 | 0.0 | | | 0.2 |
| Gain (loss) on debt retirement | -4.6 | | | | | | | |
| Other | | | -0.1 | 0.0 | 0.0 | | | |
| Pre-tax income | 0.4 | -2.7 | -11.6 | -6.8 | -5.6 | -2.3 | 0.0 | 0.0 |
| Income taxes | 2.4 | 0.8 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 |
| Tax rate | 610.2% | | | 0.0% | | 0.0% | 29.0% | |
| Minority interest | 0.1 | | | | | | | |
| Net income | -2.0 | -3.4 | -11.6 | -6.8 | -5.7 | -2.3 | 0.0 | -0.2 |
| Net margin | -1.4% | -3.0% | -37.5% | -28.0% | -137.0% | -1099.7% | 0.6% | -18.0% |
| |
| Basic EPS [+] | ($0.05) | ($0.09) | ($0.41) | | | | | ($0.02) |
| Growth | -45.8% | -78.5% | | | | | | 418.6% |
| Diluted EPS [+] | ($0.05) | ($0.09) | ($0.41) | | | | | ($0.02) |
| Growth | -45.8% | -78.5% | | | | | | 418.6% |
| |
| Shares outstanding (basic) [+] | 41.4 | 38.6 | 28.1 | | | | | 7.8 |
| Growth | 7.2% | 37.3% | | | | | | 0.0% |
| Shares outstanding (diluted) [+] | 41.4 | 38.6 | 28.1 | | | | | 7.8 |
| Growth | 7.2% | 37.3% | | | | | | 0.0% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |